Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Synteract, Inc.
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
Savara Inc.
ClinicalTrials.gov Identifier:
NCT01746095
First received: December 6, 2012
Last updated: August 19, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: November 2014
  Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)